Cancer · 1973 · 69 citations · 8 references
MedicineOncologyPharmacologyCancer PharmacologyChemotherapyMedical OncologyChemotherapy Toxicity ManagementCytotoxic ChemotherapyHematologic ToxicityHematologic Toxicity ManagementToxicity ManagementBone Marrow DosimetryChemotherapy Dose OptimizationChemotherapy Dose-limiting ToxicityDose-limiting Hematologic ToxicityHematologic Toxicity AssessmentHepatocellular ToxicityMarrow Reserve AssessmentWell-differentiated Tumors
CCNU (1-[2-chloroethyl]-3-cyclohexyl-1-nitrosourea, NSC-79037), was used to treat 141 evaluable patients with a variety of advanced malignancies, 56% of whom had not received prior chemotherapy. Patients with an adequate bone marrow reserve received 130 mg/m2 as the initial dose and those with an impaired reserve received 100 mg/m2. Therapy was repeated every 6 weeks and the dosage modified according to the hematologic toxicity. Responses greater than 50% reduction in tumor size were noted in 26 patients; stable disease or reduction in tumor size of less than 50% was observed in 21 patients. The well-differentiated adenocarcinomas and squamous cell tumors appeared to be least sensitive to CCNU. Bone marrow depression was the major dose-limiting factor. Without adequate antiemetic therapy, all patients would have had nausea and vomiting. Hepatocellular toxicity was noted in two patients.
8
Clinical trials with 1,3-bis(2-chloroethyl)-1-nitrosourea, NSC-409962.
De Vita Vt, Carbone Pp, Owens Ah et al. · PubMed · 1965 · 219 citations
Medicine, Oncology, Pharmacology +14
Clinical studies with 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (NSC 79037).
Heine H. Hansen, Oleg S. Selawry, Franco M. Muggia et al. · PubMed · 1971 · 93 citations
Medicine, Oncology, Pharmacology +8